Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Relapsed Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Study leads

yuankai shi, doctor
Principal Investigator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Relapsed Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Jilin City, China

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Springdale, United States · Fullerton, United States

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Beijing, China · Harbin, China

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Relapsed Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Chicago, United States